- Home
- SILC vs INKT Comparison
SILC vs INKT Comparison
Compare SILC & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILC
- INKT
- Stock Information
- Founded
- SILC 1987
- INKT 2017
- Country
- SILC Israel
- INKT United States
- Employees
- SILC N/A
- INKT N/A
- Industry
- SILC Computer Manufacturing
- INKT Medicinal Chemicals and Botanical Products
- Sector
- SILC Technology
- INKT Health Care
- Exchange
- SILC Nasdaq
- INKT Nasdaq
- Market Cap
- SILC 86.2M
- INKT 69.2M
- IPO Year
- SILC 1994
- INKT 2021
- Fundamental
- Price
- SILC $18.51
- INKT $15.09
- Analyst Decision
- SILC Hold
- INKT Buy
- Analyst Count
- SILC 1
- INKT 3
- Target Price
- SILC N/A
- INKT $37.50
- AVG Volume (30 Days)
- SILC 13.2K
- INKT 44.3K
- Earning Date
- SILC 10-30-2025
- INKT 11-13-2025
- Dividend Yield
- SILC N/A
- INKT N/A
- EPS Growth
- SILC N/A
- INKT N/A
- EPS
- SILC N/A
- INKT N/A
- Revenue
- SILC $58,651,000.00
- INKT N/A
- Revenue This Year
- SILC $6.53
- INKT N/A
- Revenue Next Year
- SILC $14.10
- INKT N/A
- P/E Ratio
- SILC N/A
- INKT N/A
- Revenue Growth
- SILC N/A
- INKT N/A
- 52 Week Low
- SILC $12.29
- INKT $4.56
- 52 Week High
- SILC $19.37
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- SILC 70.17
- INKT 51.01
- Support Level
- SILC $18.09
- INKT $13.11
- Resistance Level
- SILC $19.36
- INKT $16.20
- Average True Range (ATR)
- SILC 0.64
- INKT 1.11
- MACD
- SILC 0.22
- INKT 0.05
- Stochastic Oscillator
- SILC 75.85
- INKT 62.01
About SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.